CLINICAL TRIALS PROFILE FOR INTRON A

All Clinical Trials for INTRON A

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00005012 ↗	Safety and Effectiveness of PEG-Intron in HIV-Infected Patients	Completed	Schering-Plough	Phase 2	2000-03-01	The purpose of this study is to see if it is effective to give PEG-Intron (PEG-IFN) to HIV-infected patients who are not doing well with their current anti-HIV drug combination (HAART).
NCT00006325 ↗	Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1	1969-12-31	The purpose of this study is to see if PEG-Intron is safe and tolerated when given to children, to see how much gets into the blood and how long it stays in the blood, and to see how well it works to reduce viral load (level of HIV in the blood). PEG-Intron is an experimental drug that works differently than other anti-HIV medications. It decreases the ability of HIV to infect the T cells (a special type of cell that helps fight infection). PEG-Intron has been approved by the Food and Drug Administration (FDA) to treat hepatitis C in adults, but in this study, it is being used as an investigational agent for the treatment of HIV/AIDS. It has not been tested in children before and experience with PEG-Intron in adults is limited. (This protocol has been changed to reflect FDA approval of PEG-Intron for treating hepatitic C in adults.)
NCT00006325 ↗	Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	The purpose of this study is to see if PEG-Intron is safe and tolerated when given to children, to see how much gets into the blood and how long it stays in the blood, and to see how well it works to reduce viral load (level of HIV in the blood). PEG-Intron is an experimental drug that works differently than other anti-HIV medications. It decreases the ability of HIV to infect the T cells (a special type of cell that helps fight infection). PEG-Intron has been approved by the Food and Drug Administration (FDA) to treat hepatitis C in adults, but in this study, it is being used as an investigational agent for the treatment of HIV/AIDS. It has not been tested in children before and experience with PEG-Intron in adults is limited. (This protocol has been changed to reflect FDA approval of PEG-Intron for treating hepatitic C in adults.)
NCT00030849 ↗	Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	2001-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy with interferon alfa may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining bexarotene with interferon alfa in treating patients who have cutaneous T-cell lymphoma.
NCT00030849 ↗	Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma	Completed	Memorial Sloan Kettering Cancer Center	Phase 2	2001-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy with interferon alfa may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining bexarotene with interferon alfa in treating patients who have cutaneous T-cell lymphoma.
NCT00035360 ↗	Phase III PEG-Intron in HIV-infected Patients (Study P00738)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2002-03-01	This is a randomized, double-blind, multicenter trial testing 2 doses of PEG-Intron, 1.0mcg/kg/week and 3.0mcg/kg/week in heavily treatment-experienced HIV-infected patients compared to placebo. The study will evaluate the efficacy and safety of PEG-Intron when added to stable optimized background antiretroviral therapy in this patient population.

Clinical Trial Conditions for INTRON A

Condition Name

Condition Name for INTRON A
Intervention	Trials
Hepatitis C, Chronic	22
Hepatitis C	11
Melanoma	8
Chronic Hepatitis C	7

Condition MeSH

Condition MeSH for INTRON A
Intervention	Trials
Hepatitis C	42
Hepatitis	37
Hepatitis C, Chronic	35
Hepatitis A	35

Clinical Trial Locations for INTRON A

Trials by Country

Trials by Country for INTRON A
Location	Trials
United States	165
United Kingdom	7
Germany	6
Italy	6
France	5

Trials by US State

Trials by US State for INTRON A
Location	Trials
Texas	21
New York	13
Florida	10
Massachusetts	9
California	9

Clinical Trial Progress for INTRON A

Clinical Trial Phase

Clinical Trial Phase for INTRON A
Clinical Trial Phase	Trials
Phase 4	14
Phase 3	22
Phase 2/Phase 3	3

Clinical Trial Status

Clinical Trial Status for INTRON A
Clinical Trial Phase	Trials
Completed	61
Terminated	22
Unknown status	5

Clinical Trial Sponsors for INTRON A

Sponsor Name

Sponsor Name for INTRON A
Sponsor	Trials
Merck Sharp & Dohme Corp.	27
Schering-Plough	13
M.D. Anderson Cancer Center	9

Sponsor Type

Sponsor Type for INTRON A
Sponsor	Trials
Other	87
Industry	72
NIH	13

Last updated: May 1, 2026

INTRON A (interferon alfa-2b): Clinical-trials update, market analysis, and projections

What is INTRON A and how is it positioned in current markets?

INTRON A is interferon alfa-2b (recombinant). It is a biologic cytokine used historically across multiple disease areas, most notably:

• Melanoma (adjuvant and other regimens in the past decade and earlier)
• Chronic hepatitis B
• Chronic hepatitis C (in combination regimens historically dominated interferon-based care)
• Condyloma acuminata (genital warts)
• Hairy cell leukemia (historically)
• Multiple other on-label and off-label interferon indications depending on geography and label revisions over time

The commercial reality today is shaped by the shift away from interferon-based regimens, especially for hepatitis C, where direct-acting antivirals displaced interferon as standard of care decades ago. INTRON A has remained available in multiple markets, but at a reduced addressable population versus its peak-era use.

Core implication for projection: INTRON A’s current revenue trajectory is driven more by remaining label activity, residual patient pools, geography-specific access, and generics/biosimilars and supply economics than by new clinical uptake.

---

What does a “clinical trials update” look like for INTRON A today?

INTRON A is not associated with a broad, new-wave pipeline role comparable to late-stage assets. Clinical activity for interferon alfa-2b generally trends toward:

• post-authorization studies (where required by regulators),
• regimen comparisons vs modern standards in legacy populations,
• small prospective studies, observational registries, and combination explorations, and
• manufacturing or formulation support (as opposed to large phase 3 registration programs).

In major regulatory ecosystems, the latest years of interferon alfa-2b clinical work is heavily characterized by non-defining studies rather than large pivotal trials. That pattern is consistent with the category’s earlier displacement by targeted therapies in hepatitis C and with evolving immuno-oncology standards in melanoma and other cancers.

Operational takeaway for R&D and investment: INTRON A-like biologics are primarily assessed through label maintenance, lifecycle management, and targeted niche use rather than through new registrational development.

---

What is the current patent and exclusivity landscape that matters for INTRON A commercialization?

INTRON A was launched decades ago. The key business consequence is that brand-level market exclusivity has largely expired in major jurisdictions, leaving competition from:

• generic interferon alfa-2b products where authorized, and/or
• biologic manufacturing equivalents and alternate interferon formulations.

For business planning, that means the brand’s commercial outcomes depend primarily on:

• procurement and payer preferences,
• contracting behavior,
• supply continuity and cost,
• and the remaining clinical practices that still align with interferon alfa-2b.

---

What does market analysis indicate about INTRON A’s demand drivers?

Demand is segmented by indication history:

1) Hepatitis C: structural decline vs DAA era

Interferon alfa-2b-based regimens lost share as direct-acting antivirals (DAAs) became the standard of care. This compresses the addressable population to:

• patients with special circumstances,
• access-limited settings where DAAs are not universal,
• legacy treatment pathways,
• and compliance or coverage constraints.

2) Hepatitis B: slower decline and ongoing relevance

Chronic hepatitis B still has interferon-based pathways in certain patient subgroups. While newer therapies exist, interferon can remain part of treatment algorithms depending on region, guideline interpretation, contraindications, and payer coverage.

3) Oncology and dermatology niches: intermittent use

Historical uses in melanoma and other conditions persist mainly where clinicians still adopt interferon-based approaches or where legacy guideline positions remain. In practice, these are smaller revenue pools than the hepatitis C era.

4) Residual off-label use and local prescribing patterns

Interferons have persistent off-label prescribing in some geographies, which can smooth demand but does not typically restore brand-scale growth.

---

How do pricing and competition dynamics shape revenue prospects?

For older biologics like INTRON A, revenue is usually constrained by:

• biologic competition and interchangeability
• tender-driven pricing
• payer step therapy and prior authorization
• hospital formulary selection
• manufacturing scale and supply continuity

This creates a market profile where:

• volume growth is hard,
• price erosion is the norm,
• and revenue stability tends to depend on maintaining formulary inclusion and supply reliability.

---

What is the market size profile by geography and channel?

A practical business view is that INTRON A is most resilient in markets where:

• biosimilar and generic penetration is slower or less uniform,
• reimbursement remains available for interferon regimens,
• and regional practice still supports interferon-based treatment for specific subgroups.

Channel mix typically concentrates in:

• hospital and specialist clinics for oncology and dermatology,
• hepatology clinics for HBV,
• and procurement-driven distribution in government and large payer systems.

---

What are the revenue and market-share projections for the next 3 to 5 years?

Because INTRON A is a legacy biologic with declining category headwinds in hepatitis C and no new large registration-defining trials, the projection is structurally conservative.

Projection framework (base case)

• Trend: low-to-moderate revenue erosion driven by pricing pressure and shrinking interferon-eligible patient pools.
• Volume: stable to modest decline, depending on regional hepatitis B persistence and residual hepatitis C access constraints.
• Market share: flat to declining versus competitors and alternatives, especially in hepatitis C.

3-year outlook (directional)

• Revenue: gradual decline
• Unit demand: slight decline with regional pockets of stability
• Margin: compressed due to tender and competition

5-year outlook (directional)

• Revenue: continued slow erosion
• Brand relevance: reduced further, with remaining use concentrated in specific indications and geographies
• Risk: supply disruption or reimbursement shifts can cause sharper dips in localized markets

Bottom line: INTRON A is best modeled as a mature, declining biologic with resilient pockets, not as a growth product.

---

Key business implications

• Clinical urgency is low: no large phase 3 registration momentum typical of newer oncology or antiviral franchises.
• Market value is concentrated in access and reimbursement: stability depends on payer policy and regional guideline adoption of interferon in HBV and select niches.
• Competition pressure is structural: pricing erosion dominates over product innovation.

---

Key Takeaways

• INTRON A (interferon alfa-2b) is a mature biologic whose demand is shaped by legacy indications, especially the shift away from interferon-era hepatitis C.
• Clinical activity is likely dominated by lifecycle studies and smaller explorations rather than registration-driving trials.
• Revenue projections for the next 3 to 5 years point to gradual decline with pockets of stability, driven by regional reimbursement and residual eligible patient pools.
• Competitive and procurement dynamics, not pipeline breakthroughs, are the primary drivers of financial outcomes.

---

FAQs

1. Is INTRON A still used for hepatitis C?
   Use has largely declined due to the dominance of direct-acting antivirals; residual use persists where DAAs are not accessible or in legacy pathways.

2. What indication drives the most durability for interferon alfa-2b?
   Chronic hepatitis B can sustain more consistent demand than hepatitis C because interferon regimens can remain part of some treatment algorithms in certain regions.

3. Do new large phase 3 trials typically happen for INTRON A?
   The category’s current clinical pattern is mainly lifecycle and non-defining studies rather than pivotal phase 3 programs that change standard of care.

4. How does competition affect INTRON A pricing?
   Tendering and competition from alternatives typically drive sustained pricing pressure, which constrains revenue even when volume holds.

5. What is the most important factor for revenue stability?
   Reimbursement coverage and formulary access in specific regions and indication niches.

---

References

[1] U.S. Food and Drug Administration (FDA). INTRON A (interferon alfa-2b) prescribing information. FDA label database. https://www.accessdata.fda.gov/
[2] EMA. European public assessment reports and product information for interferon alfa-2b / INTRON A. https://www.ema.europa.eu/
[3] ClinicalTrials.gov. Interferon alfa-2b (INTRON A) studies search results. https://clinicaltrials.gov/